Brief: Index Pharmaceuticals Receives First Regulatory Approval To Start The Phase III Study Conclude With cobitolimod

Flerie AB

21/07/2021 19:26

July 21 (Reuters) - InDex Pharmaceuticals Holding AB
 INDEX.ST :
    * INDEX PHARMACEUTICALS RECEIVES FIRST REGULATORY APPROVAL
TO
START THE PHASE III STUDY CONCLUDE WITH COBITOLIMOD
    * CONCLUDE IS A GLOBAL PHASE III STUDY THAT WILL BE
CONDUCTED AT
SEVERAL HUNDRED CLINICS IN OVER 30 COUNTRIES
    * INDEX PHARMACEUTICALS- STUDY TO EVALUATE EFFICACY, SAFETY
OF
FIRST-IN-CLASS TLR9 AGONIST COBITOLIMOD FOR TREATMENT OF
LEFT-SIDED ULCERATIVE COLITIS
    * INDUCTION STUDY WILL INCLUDE 440 PATIENTS, AND PRIMARY
ENDPOINT
WILL BE CLINICAL REMISSION AT WEEK 6

Source text for Eikon:  ID:nWkr7CVTn9 
Further company coverage:  INDEX.ST 

 ((Reuters.Briefs@thomsonreuters.com;))